KissPeptin-10 5mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Kisspeptin (also called metastin; the KISS1 gene product, available as kisspeptin-10 or kisspeptin-54) is a naturally occurring neuropeptide that stimulates hypothalamic GnRH neurons to drive release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)[1][5]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Kisspeptin is an investigational research compound — it is not approved by the FDA, EMA or any regulator for human use, and human use is research-only — presented for research and educational use only.

Add 3.0 mL bacteriostatic water to one 10 mg vial → ~3.33 mg/mL (3,333 mcg/mL), a practical dilution for accurate low-volume dosing.
100–200 mcg once daily, titrated upward gradually across an 8–12 week course (about ~0.7–1.4 mg per week).
At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg; 100 mcg ≈ 3 units and 200 mcg ≈ 6 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	100 mcg (1× daily)	3 units (0.03 mL)
Weeks 3–4	150 mcg (1× daily)	4.5 units (0.045 mL)
Weeks 5–8	200 mcg (1× daily)	6 units (0.06 mL)
Weeks 9–12	200 mcg (1× daily)	6 units (0.06 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg vial → final concentration ~3.33 mg/mL (3,333 mcg/mL).
Typical daily range: 100–200 mcg once daily, raised gradually over an 8–12 week course.
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U-100 syringe. So 100 mcg = 3 units (0.03 mL) and 200 mcg = 6 units (0.06 mL); for these small volumes a 30- or 50-unit syringe improves readability.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, following a conservative titration to assess individual response[4][5]. These figures come from reference protocols, not from approved human dosing.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
At ~3.33 mg/mL each dose reads at 3–6 units; for these small volumes a 30- or 50-unit insulin syringe makes the markings easier to read. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with gradual titration.

At 100–200 mcg daily, one 10 mg vial covers roughly 8–12 weeks of dosing.
8 weeks: ~1 vial
12 weeks: ~2 vials
16 weeks: ~3 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 10 mg vial for reconstitution.
8 weeks (1 vial): ~3 mL → 1 bottle
16 weeks (3 vials): ~9 mL → 1 bottle
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Stimulate the body’s own GnRH neurons to support physiological LH/FSH and downstream sex-hormone signaling — studied in reproductive and HPG-axis research, not established for human therapeutic use[1][7].
▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
▪Dose Range: 100–200 mcg per day with gradual titration.
▪Reconstitution: 3.0 mL bacteriostatic water per 10 mg vial gives ~3.33 mg/mL for accurate low-volume measurements.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses.

▪Start: Begin at 100 mcg once daily for 1–2 weeks to assess sensitivity.
▪Titrate: Increase toward 200 mcg once daily if tolerated and necessary.
▪Target: A daily dose of about 200 mcg by weeks 5–12.
▪Cycle Length: Typically 8–12 weeks; avoid prolonged continuous use to limit tachyphylaxis[6].
▪Timing: Inject at a consistent time each day and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Kisspeptin is an investigational research compound and is not approved by the FDA, EMA or any regulator for human use[10].

How This Works

Kisspeptin (the KISS1 gene product) is an upstream trigger for the reproductive hormone cascade. On subcutaneous administration it binds the kisspeptin receptor (GPR54 / KISS1R) on GnRH neurons in the hypothalamus, prompting pulsatile release of GnRH[1][7].

That GnRH release in turn stimulates the anterior pituitary to secrete LH and FSH, which act on the gonads to support sex-steroid production and gametogenesis[8]. Because the effect is GnRH-dependent, blocking GnRH abolishes kisspeptin’s LH/FSH response — confirming it works by engaging the body’s own hypothalamic machinery[9].
Compared with direct GnRH or hCG, kisspeptin produces a more physiologic, self-limiting pattern of hormone release, which is why it has been studied as a research tool in reproductive endocrinology[10].
Important caveat: kisspeptin’s reproductive effects are documented mainly in early-phase and mechanistic research. It has not been approved by any regulator for human treatment, and any reproductive, fertility or hormone-related uses should be read as research hypotheses rather than established benefits.
Kisspeptin is not an approved medicine. It is an investigational research compound presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support healthy hormone signaling alongside the protocol.

▪Nutrition: Maintain adequate nutrition and a healthy body weight to support endogenous hormone production.
▪Activity & rest: Balance regular activity with recovery; chronic energy deficit and overtraining can suppress the HPG axis.
▪Sleep: Aim for 7–9 hours, since sleep strongly influences reproductive hormone rhythms.
▪Stress: Manage stress with evidence-based practices, since it can disrupt hypothalamic GnRH signaling.

Potential Benefits & Side Effects

What reproductive-endocrinology research describes; human evidence is early-phase and individual results vary.

▪Sex-hormone stimulation (research): Raises endogenous LH/FSH and downstream sex steroids by engaging the body’s own GnRH pulse generator, without bypassing the HPG axis[8].
▪Reproductive research (early-phase): Studied in functional hypothalamic amenorrhea and as an IVF ovulation trigger, where it can induce an LH surge with potentially lower ovarian-hyperstimulation risk than hCG[11].
▪Tolerability (research): Generally well tolerated in studies, with occasional mild injection-site reactions.
▪Note on humans: Kisspeptin remains investigational — it is not approved for human treatment, and large-scale efficacy is not established[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
▪Hormonal effects: By design it perturbs reproductive hormone levels; effects on the HPG axis should be monitored in any research setting.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for KissPeptin-10 5mg.

Kisspeptin (10mg Vial) Dosage Protocol Open source
1 Endocrine Reviews (Oxford Academic) Comprehensive review of kisspeptin and neurokinin B: role in reproduction and emerging therapeutic potential. View Source ↗ Open source
2 Endocrine Reviews (Oxford Academic) Kisspeptin stimulation of GnRH neurons and downstream LH/FSH secretion via the GPR54 receptor. View Source ↗ Open source
3 Endocrine Reviews (Oxford Academic) KiSS-1 gene discovery and the role of kisspeptin signaling in reproductive endocrinology. View Source ↗ Open source
4 Kisspeptin-10 Clinical Reference Sheet Clinical reference sheet: kisspeptin-10 starting-dose recommendations and titration guidance. View Source ↗ Open source
5 Endocrine Reviews (Oxford Academic) Dose-response relationships and titration considerations for kisspeptin administration. View Source ↗ Open source
6 Endocrine Reviews (Oxford Academic) Tachyphylaxis and desensitization considerations with prolonged kisspeptin exposure. View Source ↗ Open source
7 Endocrine Reviews (Oxford Academic) Kisspeptin mechanism: GPR54 (KISS1R) binding on GnRH neurons and pulsatile GnRH release. View Source ↗ Open source
8 Endocrine Reviews (Oxford Academic) HPG-axis cascade: GnRH stimulation of pituitary LH and FSH secretion. View Source ↗ Open source
9 Endocrine Reviews (Oxford Academic) GnRH-dependence of kisspeptin action shown by GnRH-antagonist studies. View Source ↗ Open source
10 FDA Human Drug Compounding Investigational status: kisspeptin is not approved by the FDA, EMA or other regulators for human use. View Source ↗ Open source
11 Endocrine Reviews (Oxford Academic) Physiologic advantage of kisspeptin over direct GnRH or hCG for stimulating gonadotropins. View Source ↗ Open source
12 Journal of Clinical Investigation Kisspeptin-54 triggers oocyte maturation in IVF with reduced ovarian-hyperstimulation risk. View Source ↗ Open source
13 ClinicalTrials.gov Clinical-trial registry for kisspeptin; reproductive research remains early-phase, with no approved human indication. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Peptide Systems Research peptide reconstitution and stability protocols for lyophilized peptides. View Source ↗ Open source

Contents